Search Clinical Trials in the European Union

6-12 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
341-360 of 397 trials

Chronic Limb-Threatening Ischemia: Bone Marrow Cell Therapy

We are comparing a new treatment using your own bone marrow cells with standard care for diabetic patients with severe circulation problems. The goal is to see if this therapy improves tissue oxygen levels and overall health.

Diabetic Foot SyndromeLower Limb Ischemia6-12 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCardiologyEndocrinologyInternal MedicineOrthopedics and Traumatology

Knee Surgery: Testing SRSD107 for Blood Clot Prevention

We are studying whether SRSD107 can effectively prevent blood clots in adults undergoing knee replacement surgery. We will also assess how safe it is compared to the standard treatment, enoxaparin.

Venous Thromboembolism6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyOrthopedics and Traumatology

Hidradenitis Suppurativa: Tibulizumab Study

We are evaluating the effects of tibulizumab on skin lesions and quality of life for adults with hidradenitis suppurativa. The study also looks at the safety and tolerability of this treatment.

Hidradenitis Suppurativa6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

PM14 Treatment for Soft Tissue Sarcomas and Solid Tumors

We are studying how PM14 works alone and with radiotherapy in patients with soft tissue sarcomas and other solid tumors. The goal is to find the best treatment approach and understand its safety and effectiveness.

Soft Tissue Sarcomas and Other Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncologyOrthopedics and Traumatology

Type 1 Diabetes: Once-Weekly Insulin Icodec vs. Daily Insulin Glargine

We are studying whether a new once-weekly insulin can help adults with type 1 diabetes manage their blood sugar levels as well as the standard daily insulin. This trial will also look at safety and patient experiences.

Type 1 Diabetes6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesDiabetologyEndocrinology

FT751: Safety and Tolerability Study

We are examining a new oral medication, FT751, in healthy individuals to understand its safety and how it is processed in the body. This research may help inform future treatments.

Autoimmune Disorders6-12 monthsSafety phase (I)Rheumatology

CEB-01 for Pediatric Abdominal Tumors

We are testing a new treatment for children with certain types of abdominal tumors to see if it is safe and effective alongside standard care. This study focuses on children from birth to under 18 years old.

Desmoplastic Small Round Cell TumorFibrolamellar Hepatocellular CarcinomaExtracranial Malignant Rhabdoid Tumor6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOncologyPediatrics

Stem Cell Transplant: New T Cell Therapy

We are studying a new treatment using special T cells to help prevent complications in patients receiving stem cell transplants from siblings. The goal is to see if this approach can safely reduce the need for other medications.

Healthy Participants6-12 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyInfectious DiseasesInternal Medicine

Lung Cancer: Nivolumab with Ipilimumab and Chemotherapy

We are studying a new way to administer nivolumab alongside ipilimumab and chemotherapy for patients with untreated metastatic or recurrent lung cancer. The trial aims to understand how the body reacts to this combination and its safety.

Non-small cell lung cancer6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

PMM2-CDG: GLM101 Treatment Study

We are investigating whether weekly doses of GLM101 can improve movement and coordination in people with PMM2-CDG. The study will also evaluate the safety of this new treatment compared to a placebo.

Congenital Disorder of Glycosylation (CDG)6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHepatologyNeurology

Brain Disorders: NT 0150 Study

We are investigating a new compound, NT 0150, for its safety and how it is absorbed and eliminated in the body. This research may help in developing treatments for Alzheimer's and Parkinson's disease.

Cryopyrin Associated Periodic Syndrome6-12 monthsSafety phase (I)Internal MedicineNeurology

Prostate Cancer: JSB462 and Lutetium Combination Study

We are studying a new treatment combining JSB462 with lutetium for adult men with advanced prostate cancer. The goal is to see how well this combination works and its safety compared to standard treatment.

Metastatic Castration-Resistant Prostate Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Ravulizumab for Pediatric IgA Nephropathy

We are studying how Ravulizumab works in children with Primary Immunoglobulin A Nephropathy. This research may help us understand its effects and safety in younger patients.

Immunoglobulin A Nephropathy6-12 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNephrologyPediatrics

Refractory Epilepsy: YCJ-01 Cannabis Extract

We are studying a cannabis extract to see if it can help reduce seizures in patients with difficult-to-control epilepsy due to Tuberous Sclerosis Complex. The trial will also assess the safety of this treatment.

Tuberous Sclerosis ComplexRefractory Epilepsy in Tuberous Sclerosis Complex6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Type 2 Diabetes: Insulin NNC0471-0119 via Pump

We are studying how a new insulin works in people with type 2 diabetes when delivered through an insulin pump. This research may help improve diabetes management.

Type 2 Diabetes6-12 monthsSafety phase (I)DiabetologyEndocrinology

Type 2 Diabetes: RO7795081 Medication Study

We are comparing a new medication, RO7795081, with a placebo and semaglutide in people with type 2 diabetes. The study aims to see how well it controls blood sugar and affects body weight.

Type 2 Diabetes6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementDiabetologyEndocrinology

Influenza Vaccine Study: OVX836

We are testing the OVX836 influenza vaccine in healthy adults to see if it can prevent influenza compared to a placebo. This study will also look at the vaccine's safety and how well it triggers an immune response.

Influenza6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteInfectious Diseases

PF-07999415: Tolerance Study in Healthy Adults

We are investigating how well different amounts of the medicine PF-07999415 are tolerated by healthy adults. This study will help us understand its effects in the body.

Metabolism and Nutrition Disorders6-12 monthsSafety phase (I)EndocrinologyInternal Medicine

Diabetic Macular Edema: BI 1815368 Study

We are testing whether the oral medication BI 1815368 can improve vision in people with diabetic macular edema. The study will also look at the safety of this treatment over time.

Diabetic Macular Edema6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteEndocrinologyOphthalmology

Heart Health: Orticumab for Inflammation After Heart Attack

We are studying whether orticumab can reduce inflammation in people who have had a heart attack and show elevated coronary inflammation. The trial will also evaluate the safety of this treatment.

Heart Attack6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine